Zacks: Analysts Set $11.00 Price Target for Sonoma Pharmaceuticals Inc (SNOA)

Shares of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.

Brokers have set a 1 year consensus price target of $11.00 for the company and are forecasting that the company will post ($0.60) EPS for the current quarter, according to Zacks. Zacks has also given Sonoma Pharmaceuticals an industry rank of 181 out of 265 based on the ratings given to its competitors.

SNOA has been the subject of a number of research analyst reports. Maxim Group lifted their target price on Sonoma Pharmaceuticals from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Friday, November 10th. Benchmark initiated coverage on Sonoma Pharmaceuticals in a report on Thursday, December 28th. They issued a “speculative buy” rating and a $10.00 target price for the company. Finally, Zacks Investment Research lowered Sonoma Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 5th.

Sonoma Pharmaceuticals (NASDAQ:SNOA) traded up $0.23 during mid-day trading on Monday, reaching $4.69. The company has a market capitalization of $20.66, a P/E ratio of -1.62 and a beta of 0.97. Sonoma Pharmaceuticals has a 12 month low of $4.16 and a 12 month high of $8.25. The company has a quick ratio of 4.56, a current ratio of 5.37 and a debt-to-equity ratio of 0.01.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its earnings results on Thursday, November 9th. The company reported ($0.67) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.75) by $0.08. The business had revenue of $4.33 million during the quarter, compared to analyst estimates of $3.94 million. Sonoma Pharmaceuticals had a negative return on equity of 66.71% and a negative net margin of 70.46%. sell-side analysts expect that Sonoma Pharmaceuticals will post -2.71 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Set $11.00 Price Target for Sonoma Pharmaceuticals Inc (SNOA)” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.

Get a free copy of the Zacks research report on Sonoma Pharmaceuticals (SNOA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply